Learn about Trauma Systems Therapy (TST) and its use with young patients in an interview with Glenn Saxe, MD, Arnold Simon professor and chair, Department of Child and Adolescent Psychiatry, and director, the Child Study Center.

The psychiatric community continues to debate the value of the US Food and Drug Administration's (FDA) so-called ‘black box’ warning on certain antidepressants, and a pair of opposing viewpoints was recently featured in the New England Journal of Medicine.

Brief depression screening questionnaires are popular, especially with primary care providers (PCPs). However, a new study suggests that PCPs who use these questionnaires might be prescribing antidepressants to patients who don’t need them.

Concerns about the possible risk of suicide in young people taking antidepressants are often voiced by experts and parents. But how much of a role does dosage play in the risk of suicide and self-harm among young people on antidepressants?

Concerns about the safety of psychiatric medications during pregnancy are common among psychiatrists and patients alike. In many cases, one must weigh the risks of a medication to mother or child against the risks inherent in untreated mental illness. Recent research, however, lends support to the growing data about the safety of antidepressant medications in pregnancy.

A new drug is showing rapid, long-lasting results in early rodent studies, according to a paper presented by Jeffrey Talbot of Roseman University of Health Sciences at the annual meeting of the Federation of American Societies of Experimental Biology (FASEB) in April.

Selective serotonin reuptake inhibitors (SSRIs) are widely used as the first-line treatment for depression and anxiety in children and adolescents, but they are associated with significant adverse effects (AEs). Studies have shown that up to 50% of kids experience side effects from SSRIs, depending on the sample size and the type of study.

Pharmacoepidemiologist Tamara Pringsheim, MD, describes strategies for dealing with metabolic, extrapyramidal, and hormonal side effects of antipsychotics.

All antidepressants have the potential to cause physical adverse effects, such as dry mouth, drowsiness, and dizziness. But patients often report psychological and interpersonal effects, too, and the fear of these adverse reactions sometimes leads patients to refuse these drugs. How common are non-physical side effects, such as apathy and feelings of detachment?

After a dry spell of new antidepressants—the last one to be approved was levomilnacipran (Fetzima), the active enantiomer of milnacipran (Savella) in July 2013—the FDA approved vortioxetine (Brintellix) in September. Vortioxetine is another serotonergic antidepressant. How exactly does it work, and what are its advantages over existing drugs?